What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹6 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from COLINZ LABORATORIES LTD.'s filed financials and exchange disclosures
COLINZ LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Yes. Over the trailing twelve months COLINZ LABORATORIES LTD. reported a net profit of ₹3 Cr on revenue of ₹6 Cr.
Not in the latest reported year — COLINZ LABORATORIES LTD.'s dividend payout for FY26 was nil.
Effectively yes. It holds ₹0 Cr more cash than debt. Debt stands at 0.04× equity.
On trailing P/E, COLINZ LABORATORIES LTD. ranks 13 of 169 in Pharmaceuticals — cheaper than 93% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session COLINZ LABORATORIES LTD. moves 3.37% — that is the median absolute close-to-close move across its last 267 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by COLINZ LABORATORIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
